Gilles Derome, Dr. Dana Allen, Joins CTT Pharmaceuticals Advisory Board

Toronto, Ontario / TNW-ACCESSWIRE / October 1, 2014 / The Board of Directors of Mindesta Inc. (OTCBB: MDST) today announced the appointment of Gilles Derome and Dr. Dana Allen as Advisory Board members of the firm - CTT Pharmaceuticals, effective immediately.


Gilles Derome, M. Sc. Pharmacology, MBA:

Gilles Derome brings more than twenty-five years of marketing-sales and senior management experience in pharmaceuticals combined with consulting for bio-pharmaceutical companies. Through his pharmaceutical career at Sandoz/Novartis, Gilles had the opportunity to launch several products spanned over different therapeutic areas such as immunology, oncology, neurology, asthma, cardiovascular, mental health and women health. During his tenure as Head of Scientific Development, Gilles had the pre-marketing responsibility for the entire Company's portfolio ensuring proper products positioning, pricing and reimbursement strategy to accelerate market penetration. With a special interest in products life cycle extension, Gilles orchestrated the development of a Mental Health franchise through the introduction of value-added services to a non-patented product, Clozaril. Building on these successful assignments, he became Head of the Oncology - Neuroscience Business Unit. Early 2000, Gilles started consulting for pharma and biotechnology companies including start-ups where he has been instrumental in assisting companies through providing strategic insights, market evaluations, financing, new products planning and implementation as well as business development activities. Gilles has been CEO of Alethia Therapeutics and member of the Board Gilles holds a Master in Pharmacology and a MBA from Sherbrooke University. He also participated to global training Program for Pharma Executives in development. Recently, Gilles was invited to join Montreal in Vivo Commercialization Committee, a Quebec spearheading Association for Biopharmaceutical Companies. He is also member of the Canadian Healthcare Licensing Association and the Reseau de mentorat bioSucces.

Dean Hanisch, President -CTT Pharmaceuticals stated "We are extremely pleased to bring Gilles to our hands on advisory board as he has relevant recent experience assisting start up biotech firms with advancing their projects. Gilles has launched numerous products into market in the past while acting as Head of Scientific development at Sandoz so his experience in all aspects of pre marketing and product launching couldn't be any more ideal for us going forward"

Dr. Dana Allen, DVM, MSc, Diplomate ACVIM (Internal Medicine)

Dr . Dana Allen, most recently served as Chair of the Department of Clinical Studies of the Ontario Veterinary College and in the past served as Chair of the Department of Companion Animals of the Atlantic Veterinary College and,

Dr. Allen is a 1976 graduate of the Ontario Veterinary College. Following graduation he entered small animal private practice, first in Ottawa and then Vancouver before returning to the OVC to complete a residency in small animal internal medicine and a Masters degree. He is board certified (ACVIM) in small animal internal medicine.

During his academic career he has edited, authored or contributed to a number of textbooks including Small Animal Medicine, Small Animal Cardiopulmonary Medicine and several editions of the Handbook of Veterinary Drugs, audiovisual aids, and websites including VetMedCenter.Com. He has published more than 60 papers in refereed journals and has written more than 65 chapters in textbooks. Dr. Allen has been a member of several editorial boards including the Compendium on Continuing Education, Journal of Veterinary and Comparative Orthopaedics and Traumatology, Journal of the American Animal Hospital Association and, the Merck Veterinary Manual and was just recently an associate editor for the Canadian Veterinary Journal. Currently he is the editor of Small Animal Veterinary Rounds, a Snell Medical Publication and, Editor in Chief of the Compendium of Continuing Education.

Dr. Allen's research focus has been mostly focused on diabetes mellitus and hemostasis.

Dr Pankaj Modi, CEO- CTT Pharmaceuticals stated, "Dr. Dana Allen brings two major strengths to our team. Firstly he has extensive experience completing animal clinical trials including opioid wafers that we believe we will need to continue to complete for regulatory bodies to further advance our drug delivery system in both humans and pets. Dr. Allen also has extensive experience both as a practicing veterinarian as well as in medical research so we feel this tandem will be instrumental in guiding us in regards to our future Veterinarian wafer line."


ABOUT CTT PHARMACEUTICALS:

CTT Pharma has invented and developed an ideal intra oral sublingual, fast-dissolving wafer drug delivery system complete with a mobile backend tracking software designed to increase patient compliance and prevent physical addiction.

CTT Pharma's principal asset is a patented, orally administered, fast dissolving wafer (the "Wafer")

The Wafer formulation is protected by Canadian Patent Number CA 2624110 C and US Patent Number 8,823,401 B2. The Canadian Patent, is a blanket patent covering most pharmaceutical agents (an open patent) and US Patent consist of approved opiates; such as Fentanyl, Morphine, Codeine etc.

CTT Pharma"s primary mission is to lower addiction and improve overall compliance within the pain management market specifically opiates through the use of improved drug delivery and novel IT technology. This technology platform will be targeting both the human and pets (Veterinarian) markets.

CTT Pharma's Oral fast dissolving drug delivery systems will consist of films and wafers that dissolve within a few seconds after placement in the mouth without water. The majority of drugs administered using our drug delivery system have the ability to enter the bloodstream quickly mirroring injections, are convenient and discrete and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficiency of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing.

Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breath related medications. CTT believes that its technology will be the first to gain widespread use in major markets such as Pain Management (MedWafe)(MedWafe Lite), Veterinary Medicine(VetWafe) as well as Medicinal Marijuana(Cannawafe).



For additional information, please contact:

Dean Hanisch, President
CTT Pharmaceuticals
Tel: 613 612-6060
www.cttpharmaceuticals.com



Forward Looking Statements:

This press release contains forward-looking statements, which can be identified by the use of statements that include words such as "could", "potential", "believe", "expect", "anticipate", "intend", "plan", "likely", "will" or other similar words or phrases. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. The Company does not intend, and does not assume any obligation, to update forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS RELEASE